ClinicalTrials.gg
CompletedNCT06470828Updated Aug 31, 2026Results posted

A Study of TAK-861 for the Treatment of Narcolepsy Type 1

A Phase 3 interventional study of Oveporexton and Placebo in Narcolepsy Type 1, sponsored by Takeda. Completed at 53 sites in 11 countries. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
16 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Narcolepsy by Takeda — 4 open to participants now, 6 under way, 2 of them phase 3. Narcolepsy · Takeda.

Enrollment
2nd of 12
168 · median 95
Started
2024
with 1 other
Phase 3
3 of 16
none open now
Registered
10th of 16
by date

Among the 16 studies in Narcolepsy by Takeda, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 in phase 3, and was the 10th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

4 of the 16 studies in Narcolepsy by Takeda are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 16 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Narcolepsy by Takeda, or all of them as a file.
02

Study summary

The main aim of this study is to learn how effective TAK-861 (oveporexton) is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 (oveporexton) is in lowering the number of sudden, unexpected attacks of muscle weakness while staying conscious (cataplexy) in a week; to learn the effect TAK-861 (oveporexton) has on participants' ability to maintain attention, participant's overall quality of life, the spectrum of narcolepsy symptoms, and daily life functions; and to learn about the safety of TAK-861 (oveporexton).

Read the detailed description

The drug being tested in this study is called TAK-861 (oveporexton). TAK-861 (oveporexton) is being tested to evaluate its efficacy and safety in people with narcolepsy type 1 (NT1).

The study will enroll approximately 152 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups:

  1. TAK-861 Dose 1
  2. TAK-861 Dose 2
  3. Placebo

The study drug will be administered for 12 weeks. This multi-center trial will be conducted globally.

03

Conditions studied

  • Narcolepsy Type 1

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant has a (BMI) within the range 18 to 40 kilograms per meter square (kg/m\^2).
  2. The participant has an International Classification of Sleep Disorders, Third Edition (ICSD-3) or International Classification of Sleep Disorders, Third Edition, Text Revision (ICSD-3-TR) diagnosis of NT1.
  3. The participant has greater than or equal to (≥)4 partial or complete episodes of cataplexy/week (WCR).
  4. The participant is positive for the human leukocyte antigen (HLA) genotype HLA-DQB1*06:02 or results from radioimmunoassay indicate the participant's cerebrospinal fluid (CSF) orexin (OX)/hypocretin-1 concentration is less than or equal to (≤)110 picograms per milliliter (pg/mL) [or less than one-third of the mean values obtained in normal participants within the same standardized assay].

Exclusion criteria

Exclusion Criteria:

  1. The participant has a current medical disorder, other than narcolepsy with cataplexy, associated with EDS.
  2. The participant: (a) has a history of myocardial infarction; (b) has a history of hepatic disease, thyroid disease, coronary artery disease, cardiac rhythm abnormality or heart failure; or (c) has any medical condition (such as unstable cardiovascular, pulmonary, renal or gastrointestinal disease).
  3. The participant has current or recent (within 6 months) gastrointestinal disease that is expected to influence the absorption of drugs.
  4. The participant has a history of cancer in the past 5 years.
  5. The participant has a clinically significant history of head injury or head trauma.
  6. The participant has a history of epilepsy, seizure, or convulsion.
  7. The participant has a history of cerebral ischemia, (\<5 years from screening), intracranial aneurysm, or arteriovenous malformation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
168 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received oveporexton (OVE)-matching placebo tablets, orally, for 12 weeks.

    Drug: Placebo

  • Experimental
    OVE 1 mg BID

    Participants received OVE tablets, 1 milligram (mg), orally, for 12 weeks.

    Drug: Oveporexton

  • Experimental
    OVE 2 mg BID

    Participants received OVE tablets, 2 mg, orally, for 12 weeks.

    Drug: Oveporexton

Interventions

  • Oral tablet.

    Also known as: TAK-861

  • DrugPlacebo

    OVE-matching placebo tablet.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in Mean Sleep Latency From the 4 Maintenance of Wakefulness Test (MWT) Wake Trials

    The MWT evaluates a person's ability to remain awake under soporific conditions for a defined period of time. Because there is no biological measure of wakefulness, wakefulness is measured indirectly by the inability or delayed tendency to fall asleep. This tendency to fall asleep is measured via electroencephalography-derived sleep latency in the MWT. The MWT consists of four 40-minute sessions (trials) done 2 hours apart. Sleep latency in each session was recorded. Participants were required to stay awake in between the four sessions. A positive change from baseline indicates an improvement. The linear mixed effects model for repeated measures (MMRM) was used for analysis.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline to Week 12 in Epworth Sleepiness Scale (ESS) Total Score

    The ESS provides individuals with 8 different situations of daily life and asks them how likely they are to fall asleep in those situations (scored 0 to 3) and to try to imagine their likelihood of dozing even if they have not actually been in the identical situation; the scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness. A negative change from baseline indicates an improvement. The linear MMRM was used for analysis.

    Time frame: Baseline, Week 12

  2. Weekly Cataplexy Rate (WCR) at Week 12

    Participants completed a daily participant-reported cataplexy diary to record self-reported episodes of cataplexy attacks. WCR = (total number of cataplexy attacks over a number of non-missing diary days for a given period/number of non-missing diary days in that period)\*7. The generalized estimating equations (GEE) model was used for analysis. Reported here is the estimated mean of incidence rate with a 95 percent (%) confidence interval (CI).

    Time frame: Week 12

  3. Change From Baseline to Week 12 in Mean Number of Lapses on the Psychomotor Vigilance Test (PVT)

    The PVT is a simple reaction performance task that aims to measure sustained attention. The mean number of lapses (delayed responses to a visual cue from intraday sessions) from the two 10-minute intraday sessions was used as a measure of objective sustained attention. A negative change from baseline indicates an improvement. A constrained Longitudinal Data Analysis (cLDA) model was used to analyze the mean number of lapses and to estimate change from baseline at each visit.

    Time frame: Baseline, Week 12

  4. Responder Rate on Patient Global Impression of Change (PGI-C) Score at Week 12

    The PGI-C is a participant self-rated scale to assess change in daytime sleepiness and overall narcolepsy symptoms. The PGI-C includes 7 items being scored from 1 (best outcome) to 7 (worst outcome) with 4 being no change. Responders were the participants reporting "1=very much improved" or "2=much improved" on PGI-C. Responder rate (proportion of participants who were responders) was estimated using a GEE model.

    Time frame: Week 12

  5. Change From Baseline to Week 12 in Narcolepsy Severity Scale for Clinical Trials (NSS-CT) Total Score

    The NSS-CT is a 15-item self-administered questionnaire that assesses the severity and consequences of the 5 major narcolepsy symptoms such as daytime sleepiness, cataplexy, hallucinations, sleep paralysis, and disturbed nighttime sleep (DNS) with a total score range of 0 to 57 (sum of 6 items that assess symptoms severity are rated using a six-point Likert scale \[0-5\] and 9 items that describe the symptom effect on daily life are rated using a four-point Likert scale \[0-3\]). Higher total scores mean a worse outcome. A negative change from baseline indicates an improvement. The linear MMRM was used for analysis.

    Time frame: Baseline, Week 12

  6. Change From Baseline to Week 12 in Functional Impacts of Narcolepsy Instrument (FINI) Domain Scores

    The FINI measures the functional impacts of narcolepsy across 6 domains Tiredness (items 1-7), Cognitive Functioning (items 8-12), Cataplexy (items 13-17), Social Activities (items 18-21), Everyday Activities (items 22-25), and Everyday Responsibilities (items 26-28). Each item asks about the impact that narcolepsy has had on their daily functioning during the past 7 days, and is scored from 0 to 4, where 0 indicates the best health and 4 the worst. An average score is calculated for each domain and then standardized to a 0-100 scale, where 0 indicates the best health and 100 the worst health. Standardized score = average score/4 × 100. A negative change from baseline indicates and improvement. The linear MMRM was used for analysis.

    Time frame: Baseline, Week 12

  7. Change From Baseline to Week 12 in Short Form-36 Survey (SF-36) Mental and Physical Component Scores

    The SF-36 is participant-reported survey of participant health that assesses the quality of life and includes both physical and mental components. The scores for each component range from 0 to 100. Higher scores represent better health-related quality of life. A positive change from baseline indicates an improvement. The linear MMRM was used for analysis.

    Time frame: Baseline, Week 12

  8. Number of Participants With At Least One Treatment-Emergent Adverse Event (TEAE)

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product.

    Time frame: Up to 16 weeks

07

Results

Posted Aug 31, 2026

Participant flow

Participants took part in the study at various investigative sites globally from 02 July 2024 to 03 June 2025.

Participant flow — Overall Study
MilestonePlaceboOVE 1 mg BIDOVE 2 mg BID
Started416166
Completed365764
Not completed542
Withdrew: Lost to follow-up010
Withdrew: Adverse event130
Withdrew: Protocol deviation201
Withdrew: Withdrawal by participant201

Outcome measures

PrimaryChange From Baseline to Week 12 in Mean Sleep Latency From the 4 Maintenance of Wakefulness Test (MWT) Wake Trials

The MWT evaluates a person's ability to remain awake under soporific conditions for a defined period of time. Because there is no biological measure of wakefulness, wakefulness is measured indirectly by the inability or delayed tendency to fall asleep. This tendency to fall asleep is measured via electroencephalography-derived sleep latency in the MWT. The MWT consists of four 40-minute sessions (trials) done 2 hours apart. Sleep latency in each session was recorded. Participants were required to stay awake in between the four sessions. A positive change from baseline indicates an improvement. The linear mixed effects model for repeated measures (MMRM) was used for analysis.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · minutes
Change From Baseline to Week 12 in Mean Sleep Latency From the 4 Maintenance of Wakefulness Test (MWT) Wake Trials
minutesPlaceboOVE 1 mg BIDOVE 2 mg BID
Change From Baseline to Week 12 in Mean Sleep Latency From the 4 Maintenance of Wakefulness Test (MWT) Wake Trials-1.32 ± 1.50212.51 ± 1.28415.87 ± 1.205
Statistical analysis
  • Placebo vs OVE 1 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: 13.83 · 95% CI 10.23 to 17.44LS in LS Mean Difference denotes least squares.
  • Placebo vs OVE 2 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: 17.2 · 95% CI 13.66 to 20.73
SecondaryChange From Baseline to Week 12 in Epworth Sleepiness Scale (ESS) Total Score

The ESS provides individuals with 8 different situations of daily life and asks them how likely they are to fall asleep in those situations (scored 0 to 3) and to try to imagine their likelihood of dozing even if they have not actually been in the identical situation; the scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness. A negative change from baseline indicates an improvement. The linear MMRM was used for analysis.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in Epworth Sleepiness Scale (ESS) Total Score
score on a scalePlaceboOVE 1 mg BIDOVE 2 mg BID
Change From Baseline to Week 12 in Epworth Sleepiness Scale (ESS) Total Score-1.42 ± 0.794-9.42 ± 0.679-11.17 ± 0.618
Statistical analysis
  • Placebo vs OVE 1 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -8 · 95% CI -9.87 to -6.13
  • Placebo vs OVE 2 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -9.75 · 95% CI -11.59 to -7.90
SecondaryWeekly Cataplexy Rate (WCR) at Week 12

Participants completed a daily participant-reported cataplexy diary to record self-reported episodes of cataplexy attacks. WCR = (total number of cataplexy attacks over a number of non-missing diary days for a given period/number of non-missing diary days in that period)\*7. The generalized estimating equations (GEE) model was used for analysis. Reported here is the estimated mean of incidence rate with a 95 percent (%) confidence interval (CI).

Time frame:
Week 12
Reported as:
Mean · cataplexy attacks per week
Weekly Cataplexy Rate (WCR) at Week 12
cataplexy attacks per weekPlaceboOVE 1 mg BIDOVE 2 mg BID
Weekly Cataplexy Rate (WCR) at Week 1234.04 (22.70 to 51.06)11.50 (7.33 to 18.03)12.80 (9.24 to 17.71)
Statistical analysis
  • Placebo vs OVE 1 mg BID · GEE · p = <0.001 (The analysis used a GEE model.) · Incidence rate ratio (irr): 0.34 · 95% CI 0.20 to 0.57
  • Placebo vs OVE 2 mg BID · GEE · p = <0.001 (The analysis used a GEE model.) · Irr: 0.38 · 95% CI 0.23 to 0.61
SecondaryChange From Baseline to Week 12 in Mean Number of Lapses on the Psychomotor Vigilance Test (PVT)

The PVT is a simple reaction performance task that aims to measure sustained attention. The mean number of lapses (delayed responses to a visual cue from intraday sessions) from the two 10-minute intraday sessions was used as a measure of objective sustained attention. A negative change from baseline indicates an improvement. A constrained Longitudinal Data Analysis (cLDA) model was used to analyze the mean number of lapses and to estimate change from baseline at each visit.

Time frame:
Baseline, Week 12
Reported as:
Mean · number of lapses
Change From Baseline to Week 12 in Mean Number of Lapses on the Psychomotor Vigilance Test (PVT)
number of lapsesPlaceboOVE 1 mg BIDOVE 2 mg BID
Change From Baseline to Week 12 in Mean Number of Lapses on the Psychomotor Vigilance Test (PVT)2.09 (-1.57 to 5.74)-7.60 (-9.87 to -5.32)-8.43 (-10.61 to -6.25)
Statistical analysis
  • Placebo vs OVE 1 mg BID · cLDA Model · p = <0.001 · Mean difference (net): -9.68 · 95% CI -13.61 to -5.75
  • Placebo vs OVE 2 mg BID · cLDA Model · p = <0.001 · Mean difference (net): -10.51 · 95% CI -14.41 to -6.62
SecondaryResponder Rate on Patient Global Impression of Change (PGI-C) Score at Week 12

The PGI-C is a participant self-rated scale to assess change in daytime sleepiness and overall narcolepsy symptoms. The PGI-C includes 7 items being scored from 1 (best outcome) to 7 (worst outcome) with 4 being no change. Responders were the participants reporting "1=very much improved" or "2=much improved" on PGI-C. Responder rate (proportion of participants who were responders) was estimated using a GEE model.

Time frame:
Week 12
Reported as:
Number · proportion of participants
Responder Rate on Patient Global Impression of Change (PGI-C) Score at Week 12
proportion of participantsPlaceboOVE 1 mg BIDOVE 2 mg BID
Responder Rate on Patient Global Impression of Change (PGI-C) Score at Week 120.21 (0.07 to 0.35)0.69 (0.55 to 0.83)0.94 (0.88 to 1.01)
Statistical analysis
  • Placebo vs OVE 1 mg BID · GEE · p = <0.001 (The analysis used a GEE model.) · Odds ratio (or): 8.44 · 95% CI 3.22 to 22.12
  • Placebo vs OVE 2 mg BID · GEE · p = <0.001 (The analysis used a GEE model.) · Odds ratio (or): 62.17 · 95% CI 16.40 to 235.60
SecondaryChange From Baseline to Week 12 in Narcolepsy Severity Scale for Clinical Trials (NSS-CT) Total Score

The NSS-CT is a 15-item self-administered questionnaire that assesses the severity and consequences of the 5 major narcolepsy symptoms such as daytime sleepiness, cataplexy, hallucinations, sleep paralysis, and disturbed nighttime sleep (DNS) with a total score range of 0 to 57 (sum of 6 items that assess symptoms severity are rated using a six-point Likert scale \[0-5\] and 9 items that describe the symptom effect on daily life are rated using a four-point Likert scale \[0-3\]). Higher total scores mean a worse outcome. A negative change from baseline indicates an improvement. The linear MMRM was used for analysis.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in Narcolepsy Severity Scale for Clinical Trials (NSS-CT) Total Score
score on a scalePlaceboOVE 1 mg BIDOVE 2 mg BID
Change From Baseline to Week 12 in Narcolepsy Severity Scale for Clinical Trials (NSS-CT) Total Score-2.99 ± 1.446-17.36 ± 1.224-19.87 ± 1.106
Statistical analysis
  • Placebo vs OVE 1 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -14.37 · 95% CI -17.81 to -10.93
  • Placebo vs OVE 2 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -16.88 · 95% CI -20.24 to -13.52
SecondaryChange From Baseline to Week 12 in Functional Impacts of Narcolepsy Instrument (FINI) Domain Scores

The FINI measures the functional impacts of narcolepsy across 6 domains Tiredness (items 1-7), Cognitive Functioning (items 8-12), Cataplexy (items 13-17), Social Activities (items 18-21), Everyday Activities (items 22-25), and Everyday Responsibilities (items 26-28). Each item asks about the impact that narcolepsy has had on their daily functioning during the past 7 days, and is scored from 0 to 4, where 0 indicates the best health and 4 the worst. An average score is calculated for each domain and then standardized to a 0-100 scale, where 0 indicates the best health and 100 the worst health. Standardized score = average score/4 × 100. A negative change from baseline indicates and improvement. The linear MMRM was used for analysis.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in Functional Impacts of Narcolepsy Instrument (FINI) Domain Scores
score on a scalePlaceboOVE 1 mg BIDOVE 2 mg BID
Tiredness: Week 12-2.13 ± 3.664-35.22 ± 3.175-48.16 ± 2.858
Cognitive Functioning: Week 123.20 ± 3.572-27.50 ± 3.080-34.72 ± 2.747
Cataplexy: Week 12-1.35 ± 3.301-19.52 ± 2.744-23.78 ± 2.513
Social Activities: Week 12-3.12 ± 3.858-28.32 ± 3.248-34.27 ± 2.979
Everyday Activities: Week 12-5.70 ± 3.564-37.78 ± 3.016-49.00 ± 2.778
Everyday Responsibilities: Week 12-8.71 ± 4.310-35.62 ± 3.639-43.05 ± 3.336
Statistical analysis
  • Placebo vs OVE 1 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -33.09 · 95% CI -41.84 to -24.33
  • Placebo vs OVE 2 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -46.02 · 95% CI -54.53 to -37.52
  • Placebo vs OVE 1 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -30.7 · 95% CI -39.21 to -22.19
  • Placebo vs OVE 2 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -37.92 · 95% CI -46.17 to -29.66
  • Placebo vs OVE 1 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -18.18 · 95% CI -26.01 to -10.34
  • Placebo vs OVE 2 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -22.43 · 95% CI -30.09 to -14.77
  • Placebo vs OVE 1 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -25.2 · 95% CI -34.29 to -16.11
  • Placebo vs OVE 2 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -31.14 · 95% CI -40.07 to -22.22
  • Placebo vs OVE 1 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -32.09 · 95% CI -40.61 to -23.56
  • Placebo vs OVE 2 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -43.3 · 95% CI -51.62 to -34.97
  • Placebo vs OVE 1 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -26.9 · 95% CI -37.19 to -16.62
  • Placebo vs OVE 2 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -34.34 · 95% CI -44.41 to -24.27
SecondaryChange From Baseline to Week 12 in Short Form-36 Survey (SF-36) Mental and Physical Component Scores

The SF-36 is participant-reported survey of participant health that assesses the quality of life and includes both physical and mental components. The scores for each component range from 0 to 100. Higher scores represent better health-related quality of life. A positive change from baseline indicates an improvement. The linear MMRM was used for analysis.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in Short Form-36 Survey (SF-36) Mental and Physical Component Scores
score on a scalePlaceboOVE 1 mg BIDOVE 2 mg BID
Mental Component Summary (MCS): Week 12-1.74 ± 1.5485.04 ± 1.2928.36 ± 1.162
Physical Component Summary (PCS): Week 120.37 ± 0.9085.90 ± 0.7616.63 ± 0.70
Statistical analysis
  • Placebo vs OVE 1 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: 6.79 · 95% CI 3.05 to 10.53
  • Placebo vs OVE 2 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: 10.11 · 95% CI 6.50 to 13.72
  • Placebo vs OVE 1 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: 5.54 · 95% CI 3.40 to 7.67
  • Placebo vs OVE 2 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: 6.26 · 95% CI 4.17 to 8.35
SecondaryNumber of Participants With At Least One Treatment-Emergent Adverse Event (TEAE)

An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product.

Time frame:
Up to 16 weeks
Reported as:
Count of participants · Participants
Number of Participants With At Least One Treatment-Emergent Adverse Event (TEAE)
ParticipantsPlaceboOVE 1 mg BIDOVE 2 mg BID
Number of Participants With At Least One Treatment-Emergent Adverse Event (TEAE)225259

Adverse events

Collected over Up to 16 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/41 (0%)0/41 (0%)15/41 (36.6%)
OVE 1 mg BID0/60 (0%)1/60 (1.7%)47/60 (78.3%)
OVE 2 mg BID0/66 (0%)1/66 (1.5%)57/66 (86.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboOVE 1 mg BIDOVE 2 mg BID
UreterolithiasisRenal and urinary disorders0/411/600/66
Non-specific chest painGeneral disorders0/410/601/66
Most frequent other events
Most frequent other events
EventPlaceboOVE 1 mg BIDOVE 2 mg BID
InsomniaPsychiatric disorders0/4132/6038/66
PollakiuriaRenal and urinary disorders3/4132/6036/66
Micturition urgencyRenal and urinary disorders1/419/6012/66
NasopharyngitisInfections and infestations6/416/6010/66
HeadacheNervous system disorders5/414/6010/66
Salivary hypersecretionGastrointestinal disorders0/415/604/66
Weight increasedInvestigations3/412/604/66
MigraineNervous system disorders3/410/601/66

Baseline characteristics

Full Analysis Set (FAS) consisted of all participants who were randomized.

Age, Continuous
Age, Continuous(years)PlaceboOVE 1 mg BIDOVE 2 mg BIDTotal
Mean30.9 ± 12.7133.5 ± 11.8229.7 ± 9.6431.4 ± 11.31
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboOVE 1 mg BIDOVE 2 mg BIDTotal
Female24284698
Male17332070
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboOVE 1 mg BIDOVE 2 mg BIDTotal
Hispanic or Latino36514
Not Hispanic or Latino22233075
Unknown or Not Reported16323179
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboOVE 1 mg BIDOVE 2 mg BIDTotal
American Indian or Alaska Native0011
Asian6101026
Native Hawaiian or Other Pacific Islander0000
Black or African American4307
White15172759
More than one race1001
Unknown or Not Reported15312874
08

Study locations

53 sites
  • Takeda Site 48
    Phoenix, Arizona 85054, United States
  • Takeda Site 39
    Redwood City, California 94063, United States
  • Takeda Site 31
    Santa Ana, California 92705, United States
  • Takeda Site 18
    Upland, California 91786, United States
  • Takeda Site 4
    Orlando, Florida 32803, United States
  • Takeda Site 3
    Atlanta, Georgia 30328, United States
  • Takeda Site 45
    Boston, Massachusetts 02115, United States
  • Takeda Site 5
    St Louis, Missouri 63123, United States
  • Takeda Site 2
    Denver, North Carolina 28037, United States
  • Takeda Site 6
    Cincinnati, Ohio 45227, United States
  • Takeda Site 42
    Cleveland, Ohio 44195, United States
  • Takeda Site 49
    Danville, Pennsylvania 17821, United States
  • Takeda Site 1
    Columbia, South Carolina 29201, United States
  • Takeda Site 44
    Dallas, Texas 75231, United States
  • Takeda Site 10
    Norfolk, Virginia 23510, United States
  • Takeda Site 21
    Ottawa, Ontario K2A 3Z3, Canada
  • Takeda Site 11
    Toronto, Ontario M5S 3A3, Canada
  • Takeda Site 50
    Montreal, Quebec H4J 1C5, Canada
  • Takeda Site 25
    Montpellier, Herault 34090, France
  • Takeda Site 43
    Toulouse, Midi-Pyrenees 31059, France
  • Takeda Site 40
    Lyon, 69004, France
  • Takeda Site 29
    Paris, 75013, France
  • Takeda Site 47
    Regensberg, Bavaria 93053, Germany
  • Takeda Site 34
    Berlin, 10117, Germany
  • Takeda Site 26
    Schwerin, 19053, Germany
  • Takeda Site 32
    Rome, Lazio OO133, Italy
  • Takeda Site 30
    Bologna, 40139, Italy
  • Takeda Site 16
    Kurume-shi, Fukuka-Ken 830-0011, Japan
  • Takeda Site 13
    Kitakyushu-shi, Fukuoka 802-0084, Japan
  • Takeda Site 14
    Fukuoka, Fukuoka-Shi Hakata-Ku 812-0025, Japan
  • Takeda Site 9
    Kohoku, Kanagawa 222-0033, Japan
  • Takeda Site 7
    Kumamoto, Kumamoto 861-0954, Japan
  • Takeda Site 17
    Isahaya-shi, Nagasaki 854-0081, Japan
  • Takeda Site 15
    Urasoe-Shi, Okinawa 901-2132, Japan
  • Takeda Site 12
    Yodogawa, Osaka 532-0003, Japan
  • Takeda Site 8
    Bunkyo-ku, Tokyo 112-0012, Japan
  • Takeda Site 19
    Kodaira-shi, Tokyo 187-8551, Japan
  • Takeda Site 20
    Shibuya-ku, Tokyo 151-0053, Japan
  • Takeda Site 28
    Zwolle, Netherlands
  • Takeda Site 27
    Bergen, Hordaland 5021, Norway
  • Takeda Site 33
    Oslo, 450, Norway
  • Takeda Site 37
    Vitoria-Gasteiz, Alava 1004, Spain
  • Takeda Site 38
    Castellon, Castellon 12004, Spain
  • Takeda Site 35
    Barcelona, 8035, Spain
  • Takeda Site 36
    Barcelona, O8036, Spain
  • Takeda Site 24
    Madrid, 28046, Spain
  • Takeda Site 41
    Valencia, 46600, Spain
  • Takeda Site 22
    Barmelweid, Canton of Aargau 5017, Switzerland
  • Takeda Site 23
    Bern, 3010, Switzerland
  • Takeda Site 51
    Lugano, CH-6900, Switzerland
  • Takeda Site 46
    Cambridge, CB2 OAY, United Kingdom
  • Takeda Site 52
    London, SE1 9RT, United Kingdom
  • Takeda Site 53
    London, W1G 9ST, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Jun 2025, 11 months.

Results were first posted in Aug 2026, 1 year 2 months after primary completion.

Of 14 phase 3 interventional studies under Narcolepsy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2024
First posted
Jun 24, 2024
StartActual
Jul 2, 2024
Primary completionActual
Jun 3, 2025
CompletionActual
Jun 3, 2025
Results first posted
Aug 31, 2026
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06470828
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jun 24, 2024
Start date
Jul 2, 2024
Primary completion
Jun 3, 2025
Completion
Jun 3, 2025
Results posted
Aug 31, 2026
Last update
Aug 31, 2026

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oveporexton

Start the discussion